Q-TWiST Analysis to Assess Benefit–Risk of Pembrolizumab in Patients with PD-L1–Positive Advanced or Metastatic Non-small Cell Lung Cancer

Overview of attention for article published in PharmacoEconomics, December 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (83rd percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

news: 1 news outlet
twitter: 2 X users

facebook: 1 Facebook page

Readers on

mendeley: 55 Mendeley

Summary News X Facebook

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 1,513 followers.

Q-TWiST Analysis to Assess Benefit013Risk of Pembrolizumab in Patients with PD-L1013Positive Advanced ... https://t.co/ovCFuxpxZz

04 Feb 2022

Reply Repost Favourite

#HealthEconJA Q-TWiST Analysis to Assess Benefit–Risk of Pembrolizumab in Patients with PD-L1–Positive Advanced or Metastatic Non-small Cell Lung Cancer https://t.co/fYFYHEnOHY

04 Dec 2018

Reply Repost Favourite